Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

Guo L, Dong X, Ma J, Liu M, Lu Y, Wang H, Li Q, Li L, Deng Y, Xu J

The lancet. Diabetes & endocrinology27 Oct 2025Cited by 4 (Europe PMC)

PMID41167231DOI10.1016/s2213-8587(25)00248-7PepBankPUB-41167231

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. 18 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, tirzepatide 10 mg lowered HbA1c more than placebo at week 40.
In plain wordsIn adults with type 2 diabetes on insulin, tirzepatide 10 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline at week 40, 10 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.39%
tirzepatide 10 mg
HbA1c change
−0.91%
placebo
Difference vs placebo
−1.48%
tirzepatide 10 mg
Source sentences
Summary
Patients receiving tirzepatide had greater reductions in HbA_1c from baseline at week 40 than those receiving placebo (-2·39% [SE 0·13] in the 10 mg group, and -2·37% [0·13] in the 15 mg group vs -0·91% [0·12] in the placebo group; difference vs placebo -1·48% [97·5% CI -1·87 to -1·08; p<0…
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, tirzepatide 15 mg lowered HbA1c more than placebo at week 40.
In plain wordsIn adults with type 2 diabetes on insulin, tirzepatide 15 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline at week 40, 15 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
HbA1c change
−2.37%
tirzepatide 15 mg
HbA1c change
−0.91%
placebo
Difference vs placebo
−1.45%
tirzepatide 15 mg
Source sentences
Summary
and -2·37% [0·13] in the 15 mg group vs -0·91% [0·12] in the placebo group; difference vs placebo -1·48% [97·5% CI -1·87 to -1·08; p<0·0001] for the 10 mg group and -1·45% [-1·85 to -1·06; p<0·0001] for the 15 mg group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723102
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, diarrhoea was more frequent with tirzepatide 5 mg than with placebo.
In plain wordsMore people taking tirzepatide 5 mg with insulin had diarrhoea than people taking placebo.
Peptide
Tirzepatide
Outcome
IncreaseDiarrhoea, 5 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
26%
tirzepatide 5 mg
Incidence
8%
placebo
Source sentences
Summary
diarrhoea (17 [26%; 95% CI 17-38] of 65 in the tirzepatide 5 mg group, 24 [37%; 26-49] of 65 in the tirzepatide 10 mg group, and 23 [37%; 26-49] of 63 in the tirzepatide 15 mg group vs five [8%; 3-17] of 64 in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723103
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, diarrhoea was more frequent with tirzepatide 10 mg than with placebo.
In plain wordsMore people taking tirzepatide 10 mg with insulin had diarrhoea than people taking placebo.
Peptide
Tirzepatide
Outcome
IncreaseDiarrhoea, 10 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
37%
tirzepatide 10 mg
Incidence
8%
placebo
Source sentences
Summary
diarrhoea (17 [26%; 95% CI 17-38] of 65 in the tirzepatide 5 mg group, 24 [37%; 26-49] of 65 in the tirzepatide 10 mg group, and 23 [37%; 26-49] of 63 in the tirzepatide 15 mg group vs five [8%; 3-17] of 64 in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723104
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, decreased appetite was reported with tirzepatide 5 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 5 mg with insulin reported less appetite. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseDecreased appetite, 5 mg
Study
n = 65
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
5 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
29%
tirzepatide 5 mg
Incidence
0%
placebo
Source sentences
Summary
decreased appetite (19 [29%; 20-41], 16 [25%; 16-36], and 20 [32%; 22-44] vs none [0%; 0-6])
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723106
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, decreased appetite was reported with tirzepatide 10 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 10 mg with insulin reported less appetite. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseDecreased appetite, 10 mg
Study
n = 65
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
25%
tirzepatide 10 mg
Incidence
0%
placebo
Source sentences
Summary
decreased appetite (19 [29%; 20-41], 16 [25%; 16-36], and 20 [32%; 22-44] vs none [0%; 0-6])
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723107
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, upper respiratory tract infection occurred at a rate similar to placebo with tirzepatide 5 mg.
In plain wordsColds and similar infections were reported at about the same rate with tirzepatide 5 mg with insulin as with placebo.
Peptide
Tirzepatide
Outcome
No significant changeUpper respiratory tract infection, 5 mg
Study
n = 65
Comparator
Placebo
Outcome group
Adverse events · Infection
Studied dose
5 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
20%
tirzepatide 5 mg
Incidence
16%
placebo
Source sentences
Summary
upper respiratory tract infection (13 [20%; 12-31], 11 [17%; 10-28], and 11 [18%; 10-29] vs ten [16%; 9-26]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723109
08HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, upper respiratory tract infection occurred at a rate similar to placebo with tirzepatide 10 mg.
In plain wordsColds and similar infections were reported at about the same rate with tirzepatide 10 mg with insulin as with placebo.
Peptide
Tirzepatide
Outcome
No significant changeUpper respiratory tract infection, 10 mg
Study
n = 65
Comparator
Placebo
Outcome group
Adverse events · Infection
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
17%
tirzepatide 10 mg
Incidence
16%
placebo
Source sentences
Summary
upper respiratory tract infection (13 [20%; 12-31], 11 [17%; 10-28], and 11 [18%; 10-29] vs ten [16%; 9-26]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723110
09HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, nausea was reported more often with tirzepatide 5 mg than with placebo.
In plain wordsSlightly more people on tirzepatide 5 mg with insulin reported nausea than people on placebo.
Peptide
Tirzepatide
Outcome
IncreaseNausea, 5 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
5%
tirzepatide 5 mg
Incidence
3%
placebo
Source sentences
Summary
nausea (three [5%; 95% CI 2-13] in the tirzepatide 5 mg group, seven [11%; 5-21] in the tirzepatide 10 mg group, and seven [11%; 5-21] in the tirzepatide 15 mg group vs two [3%; 1-11] in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723112
10HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, nausea was reported more often with tirzepatide 10 mg than with placebo.
In plain wordsMore people on tirzepatide 10 mg with insulin reported nausea than people on placebo.
Peptide
Tirzepatide
Outcome
IncreaseNausea, 10 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
11%
tirzepatide 10 mg
Incidence
3%
placebo
Source sentences
Summary
nausea (three [5%; 95% CI 2-13] in the tirzepatide 5 mg group, seven [11%; 5-21] in the tirzepatide 10 mg group, and seven [11%; 5-21] in the tirzepatide 15 mg group vs two [3%; 1-11] in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723113
11HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, vomiting was reported with tirzepatide 5 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 5 mg with insulin vomited. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseVomiting, 5 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
6%
tirzepatide 5 mg
Incidence
0%
placebo
Source sentences
Summary
vomiting (four [6%; 2-15], six [9%; 4-19], and four [6%; 3-15] vs none [0%; 0-6]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723115
12HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, vomiting was reported with tirzepatide 10 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 10 mg with insulin vomited. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseVomiting, 10 mg
Study
n = 65
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
9%
tirzepatide 10 mg
Incidence
0%
placebo
Source sentences
Summary
vomiting (four [6%; 2-15], six [9%; 4-19], and four [6%; 3-15] vs none [0%; 0-6]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723116
13HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, diarrhoea was more frequent with tirzepatide 15 mg than with placebo.
In plain wordsMore people taking tirzepatide 15 mg with insulin had diarrhoea than people taking placebo.
Peptide
Tirzepatide
Outcome
IncreaseDiarrhoea, 15 mg
Study
n = 63
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
37%
tirzepatide 15 mg
Incidence
8%
placebo
Source sentences
Summary
diarrhoea (17 [26%; 95% CI 17-38] of 65 in the tirzepatide 5 mg group, 24 [37%; 26-49] of 65 in the tirzepatide 10 mg group, and 23 [37%; 26-49] of 63 in the tirzepatide 15 mg group vs five [8%; 3-17] of 64 in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723105
14HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, decreased appetite was reported with tirzepatide 15 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 15 mg with insulin reported less appetite. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseDecreased appetite, 15 mg
Study
n = 63
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
32%
tirzepatide 15 mg
Incidence
0%
placebo
Source sentences
Summary
decreased appetite (19 [29%; 20-41], 16 [25%; 16-36], and 20 [32%; 22-44] vs none [0%; 0-6])
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723108
15HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, upper respiratory tract infection occurred at a rate similar to placebo with tirzepatide 15 mg.
In plain wordsColds and similar infections were reported at about the same rate with tirzepatide 15 mg with insulin as with placebo.
Peptide
Tirzepatide
Outcome
No significant changeUpper respiratory tract infection, 15 mg
Study
n = 63
Comparator
Placebo
Outcome group
Adverse events · Infection
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
18%
tirzepatide 15 mg
Incidence
16%
placebo
Source sentences
Summary
upper respiratory tract infection (13 [20%; 12-31], 11 [17%; 10-28], and 11 [18%; 10-29] vs ten [16%; 9-26]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723111
16HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, nausea was reported more often with tirzepatide 15 mg than with placebo.
In plain wordsMore people on tirzepatide 15 mg with insulin reported nausea than people on placebo.
Peptide
Tirzepatide
Outcome
IncreaseNausea, 15 mg
Study
n = 63
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
11%
tirzepatide 15 mg
Incidence
3%
placebo
Source sentences
Summary
nausea (three [5%; 95% CI 2-13] in the tirzepatide 5 mg group, seven [11%; 5-21] in the tirzepatide 10 mg group, and seven [11%; 5-21] in the tirzepatide 15 mg group vs two [3%; 1-11] in the placebo group)
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723114
17HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, vomiting was reported with tirzepatide 15 mg and in no placebo patient.
In plain wordsSome people on tirzepatide 15 mg with insulin vomited. No one on placebo did.
Peptide
Tirzepatide
Outcome
IncreaseVomiting, 15 mg
Study
n = 63
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Measurements
Incidence
6%
tirzepatide 15 mg
Incidence
0%
placebo
Source sentences
Summary
vomiting (four [6%; 2-15], six [9%; 4-19], and four [6%; 3-15] vs none [0%; 0-6]
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723117
18HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, gastrointestinal adverse events with tirzepatide were predominantly mild or moderate in severity.
In plain wordsStomach and gut side effects of tirzepatide with insulin were mostly mild or moderate.
Peptide
Tirzepatide
Outcome
Not applicableSeverity of gastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5-15 mg once weekly · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
were predominantly mild or moderate in severity.
1 context sentence(design, population, supporting numbers)
Summary · context
SURPASS-CN-INS was a 40-week, double-blind, multicentre, randomised, placebo-controlled, phase 3 trial done in 26 hospitals in China.
Report a problemFND-4116723118

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05691712

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Eli Lilly and Companyn = 2575 Feb 2023 to 1 Jul 2024

Diabetes Type 2 · Diabetes Mellitus · Glucose Metabolism Disorders · Metabolic Disease · Endocrine System Diseases

Trial page ClinicalTrials.govUpdated 8 Aug 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.